Thematic Session 06

Immuo-oncology: Changing treatment paradigms in renal and urothelial cancer

**Location:** Room Vienna, North Hall (Level 1)

**Chairs:** M. De Santis, Coventry (GB)
M. Kuczyk, Hanover (DE)

**Aims and objectives of this session**
This session deals with new immunotherapeutical approaches at renal and bladder cancer. For renal cancer, insights into the mechanisms of action, the efficacy of these treatment modalities in comparison with established TKI therapy for different indications, including the application within a sequential setting, should be delivered. For bladder cancer, it should become obvious to what extent and for which indications immunotherapeutic approaches can be expected to replace conventional approaches at the treatment of metastatic disease.

**10:30 - 10:40**
*State-of-the-art lecture* Immunotherapy - Impact from oncologist's point of view
T. Powles, London (GB)

**10:40 - 10:50**
*State-of-the-art lecture* Immunotherapy - Impact from surgeon's point of view
F-C.E. Von Rundstedt, Jena (DE)

**10:50 - 11:00**
*State-of-the-art lecture* Immunotherapy - Open questions and trials
L. Albiges, Villejuif (FR)

**11:00 - 11:10**
Discussion

**11:10 - 12:00**
Urothelial cancer

**11:10 - 11:25**
*State-of-the-art lecture* Biomarkers for treatment selection
S. Shariat, Vienna (AT)

**11:25 - 11:40**
*State-of-the-art lecture* Is there still a role for chemotherapy?
A. Bamias, Athens (GR)

**11:40 - 11:55**
*State-of-the-art lecture* How will immunotherapy change the treatment paradigm?
R. Jones, Glasgow (GB)

**11:55 - 12:00**
Discussion